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SUMMARY
Background
Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B
(CHB). With the availability of newer agents, their efﬁcacy on incidence of
hepatocellular carcinoma (HCC) is not well described.
Aim
To determine the efﬁcacy of oral anti-viral agents in reducing HCC risk in
relationship with other known factors.
Methods
Published studies of at least 20 CHB patients treated with an oral anti-viral
agent and followed for >2 years were analysed for incidence of HCC per
100 person years follow-up.
Results
Pooled homogeneous data from six studies showed lamivudine (LAM)
treatment (n = 3306) to reduce HCC risk by 51% compared with no treat-
ment (n = 3585) (3.3 vs. 9.7 per 100 person years, P < 0.0001). Pooled data
from 49 studies (23 with LAM; 16 with adefovir; and 10 with entecavir,
tenofovir or telbivudine) of 10 025 treated patients showed HCC incidence
of 1.3 per 100 person years, independent of the agent used. Patient age
>50 years and hepatitis B virus-DNA detectability at HCC diagnosis
increased risk of HCC by twofold with a 10-fold higher risk among patients
with cirrhosis compared with chronic hepatitis. Meta-regression showed
patient age, study location (Eastern vs. Western) and type of study (rando-
mised or not) contributed to heterogeneity.
Conclusions
Lamivudine treatment signiﬁcantly reduces the incidence of HCC compared
with no treatment. However, HCC still develops at a rate of 1.3 per 100
patient years in CHB patients receiving an oral anti-viral agent. This ﬁnd-
ing highlights the need for continued HCC surveillance, particularly in
CHB patients with inadequate viral suppression, older age and cirrhosis.
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INTRODUCTION
Worldwide chronic hepatitis B virus (HBV) infection is
the most frequently identiﬁed cause of liver disease that
predisposes patients to the development of hepatocellular
carcinoma (HCC).1, 2 Established risk factors for the
development of HCC in untreated chronic HBV patients
include subject age, male gender, the presence of cirrho-
sis, hepatitis B e antigen (HBeAg) + serostatus and
higher levels of serum HBV-DNA.2 In a large cohort of
untreated Taiwanese patients with chronic HBV followed
up for a mean of 11.4 years, high levels of HBV replica-
tion as manifest by high levels of HBV-DNA at enrol-
ment and during follow-up were independent and strong
predictors of developing HCC.3 Over the past 20 years,
ﬁve oral nucleos(t)ide analogues have been approved for
the treatment of chronic HBV with improved short- and
intermediate-term outcomes.4, 5 The newer oral anti-viral
agents, entecavir (ETV), tenofovir (TDF) and telbivudine
(TBV) have been shown to be more potent suppressors
of HBV replication compared with lamivudine (LAM)
and adefovir (ADV) with a lower likelihood of leading to
the emergence of drug-resistant HBV during prolonged
therapy.6 However, the impact of these newer agents on
the incidence of HCC is not clear due to the limited
number of treated patients and relatively short duration
of follow-up. Since the last published review in this area,
several studies employing the newer anti-viral agents
(ETV, TDF and TBV) for prolonged periods of time in
chronic HBV patients have been reported.7–11 The aim
of this systematic review was to determine the pooled
effect of the individual oral anti-viral agents in reducing
the incidence of HCC among chronic HBV patients. In
addition, analyses were undertaken to identify the role
of other clinical features on the risk of developing HCC
in chronic HBV patients receiving an oral anti-viral
agent.
METHODS
Study selection
Search strategy. Electronic databases (Medline, Cochra-
ne reviews and EMBASE, ISI Web of science) from 1995
to 2013 were searched for publications including
abstracts that were written in English. The initial search
terms were hepatitis B, treatment and HCC. The search
was later expanded using the MeSH terms lamivudine,
adefovir, entecavir, tenofovir and telbivudine and bool-
ean logic was used to combine the search terms. A man-
ual search of the references from the identiﬁed
manuscripts was also undertaken.
Study selection criteria. The following criteria were used
to select the studies: (i) patient population – adult
patients with chronic HBV (treatment na€õve as well as
treatment experienced); (ii) treatment regimen – single
or combination oral nucleos(t)ide analogues; (iii) study
design – retrospective or open-label prospective studies
with or without a control group; and (iv) outcome –
HCC at the last follow-up as determined by the
American Association for the Study of Liver Diseases cri-
teria.4, 12, 13 Only studies with a total sample size of >20
and a median follow-up of at least 2 years were included.
Studies that included HIV or HCV co-infected patients
and/or liver transplant recipients were excluded.
Assessment of study quality. A study quality score was
determined as reported earlier,6 using the following bino-
mial parameters: randomisation, blinding, control group
or not, prospective or retrospective, deﬁned inclusion cri-
teria, deﬁned intervention, deﬁned outcome, similar
baseline characteristics, intention-to-treat analysis and
follow-up on drop outs or deaths. Each parameter was
given a numerical score of 0 or 1 with an overall quality
score ranging from 0 to 10. Studies with a quality score
of <5 were rated as poor, while those ≥5 were rated as
high.
Outcome measures
The primary outcome measure in this study was the
incidence of HCC during follow-up
Data Collection
The following data ﬁelds were extracted from each of the
included studies: (i) study characteristics (author and
year of publication, country of origin, study design, sam-
ple size, study quality score); (ii) patient demographics
(age, sex, ethnicity, per cent HBeAg positive, per cent
cirrhosis, stage of cirrhosis [Child-Turcotte-Pugh (CTP)
A vs. CTP B/C)]; (iii) inclusion and exclusion criteria;
(iv) treatment details (i.e. anti-viral agent, treatment
duration, lower limit of detection of HBV-DNA assay
and median duration of follow-up); (v) response to treat-
ment (HBV-DNA negative or positive due to non-
response or virological breakthrough); and (vi) method
of HCC detection (screening or symptomatic). The inci-
dence of HCC was also determined in the following sub-
groups: anti-viral agent used, hemisphere (Western vs.
Eastern), age (<50 vs. >50 years), HBeAg status (positive
vs. negative), cirrhosis (yes vs. no), stage of cirrhosis
(CTP A vs. CTP B/C), HBV-DNA status (detectable or
undetectable) at HCC diagnosis or last follow-up visit
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and method of detection of HCC (symptomatic vs.
screening). If the outcome data were not clear from the
manuscript, the corresponding authors were contacted
for further information.
Data and Statistical Analyses
Data on HCC incidence were pooled and reported as per
100 person years of follow-up assuming a poisson distri-
bution.14 As the follow-up period was variable across
studies, this variable was weighted for the sample size in
each study that was pooled. Pooled effects with 95% con-
ﬁdence interval (CI) are reported for the uncontrolled
data. Subgroups were considered signiﬁcantly different if
there 95% CI did not overlap. Odds ratios (OR) with
95% CI are reported for studies with a control group of
untreated patients. Heterogeneity for both open and con-
trolled data was assessed using the I2 statistics of the
pooled data. Publication bias was assessed through visual
inspection of funnel plots and using the Egger’s test.
All P values < 0.05 were considered statistically signiﬁ-
cant.
If signiﬁcant heterogeneity was noted in the pooled
data, a meta-regression model was built to help identify
which variables may have contributed to the heterogene-
ity. Data were pooled and analysed using the compre-
hensive meta-analysis software (Biostat, Engelwood, NJ,
USA, http://www.meta-analysis.com/).
RESULTS
Baseline study characteristics
A total of 2562 studies were initially reviewed to select
the 49 studies included in the current analysis (Fig-
ure 1). Two independent reviewers (AKS and SH)
reviewed the study abstracts and/or manuscripts to
identify the studies that met our inclusion and exclu-
sion criteria. Studies substantially differed in regard to
sample size, year of publication, study location (Wes-
tern or Eastern hemisphere), type of study (rando-
mised, prospective nonrandomised, retrospective),
proportion of men, % with cirrhosis, oral anti-viral
agent used, follow-up duration, method for detection of
HCC and study quality score (Tables S1 and S2). Of
the 49 studies included in this analysis, LAM was used
in 23 studies [17 open-label studies including one
randomised controlled trial (RCT) and six controlled
studies including one double-blind placebo controlled
RCT]; ADV was used in 16 studies (14 open-label
studies of ADV alone or ADV+LAM combination and
three RCT comparing ADV with ETV or ADV alone
with ADV+LAM combination); ETV was used in six
studies including a RCT comparing ETV with ADV;
TBV was used in two studies including an RCT com-
paring LAM and TBV; and TDF was used in two
open-label studies.
2566 Studies searched
516 Studies of oral antivirals
58 Studies with HCC incidence data
49 Studies analysed
Excluded
Excluded
Excluded
Excluded
1002 Reviews and 85 case reports
92 Studies on IFN treatment
383 Studies on LT patients
75 Studies not reporting HCC data
6 Studies with N<20
3 Duplicate Studies
1695 HBV related studies
608 HBV treatment studies
Figure 1 | Attrition diagram for
selecting studies included in
the current meta-analysis.
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Incidence of HCC: LAM vs. no therapy
The HCC rate was signiﬁcantly lower among the LAM
treated patients that were followed up for a median of
43 months in six controlled studies [113 of 3306 (3.4%)
vs. 343 of 3571 (9.6%); P < 0.0001; OR (95% CI) of 0.48
(0.38–0.61)] (Figure 2). The pooled data from the six
controlled studies using LAM were homogeneous (I2
P = 0.14) without any evidence of publication bias
(Egger’s test P = 0.16). Results were similar irrespective
of whether ﬁxed effects or random effects model was
used for this analysis. The addition of data from a con-
trolled study of 472 ETV-treated patients and 1143
untreated controls also did not signiﬁcantly alter the
overall incidence of HCC with OR (95% CI) of 0.38
(0.23–0.64) (data not included in Figure 2).15
Incidence of HCC in chronic HBV patients treated
with oral anti-viral agents
A total of 465 HCC cases were reported in the pooled
analysis of the 10 025 chronic HBV patients treated with
the various drugs: LAM (n = 5946); ADV (n = 1929);
and other drugs including ETV (n = 879), TDF
(n = 657), TBV (n = 616) and followed up for a median
duration of 36 months. The pooled HCC incidence rate
was 1.3 (95% Poisson conﬁdence limits 1.1–1.6) per 100
person years of follow-up (Figure S1). Substantial hetero-
geneity was noted in the pooled data (I2 = 89.84;
P < 0.0001), which was further explored using meta-
regression (see below).
Subgroup analyses. Anti-viral agent used: A total of
304 HCC were diagnosed among the 5946 LAM-treated
patients treated for a median duration of 43 months (1.3
per 100 patient years). In addition, there were 95 HCC
diagnosed among the 1929 ADV-treated patients treated
for median duration of 35 months (1.5 per 100 patient
years), and 66 HCC cases among the 2150 patients trea-
ted with TBV, ETV or TDF for median duration of
42 months years (1.3 per 100 patient years). The pooled
HCC rate was similar irrespective of the oral anti-viral
agent used with overlapping of the 95% Poisson conﬁ-
dence limits (Figure 3a). As a result, all 49 studies were
pooled together when exploring other patient character-
istics in relationship with developing HCC.
Patient age: The mean patient age was <50 years in 21
studies (n = 6037) and >50 years in 28 studies
(n = 3988) (Table S3). The pooled HCC rate per 100
person years was more than twofold higher among stud-
ies with a mean patient age >50 years compared with
studies with mean patient age of <50 years, which was
statistically signiﬁcantly different (Figure 3b).
Presence of cirrhosis: Data on the incidence of HCC
were reported separately for patients with chronic HBV
and no cirrhosis in 29 studies (n = 6129) and for patients
with cirrhosis in 33 studies (n = 3359) (Table S3). The
rate of HCC was 10-fold higher among patients with
cirrhosis compared with chronic HBV patients without
Study or subgroup
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699
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998
657
201
142
17
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31
5
1
Liaw 2004
Lok 2003
Matsumoto 2005
Papatheodoridis 2005
Yuen 2007
Lamivudine
Events EventsTotal
Total (95% Cl)
Test for overall effect: Z = 6.11 (P < 0.00001)
32.7%
9.4%
0.8%
48.9%
6.8%
1.5%
0.01 0.1 1 10 100
Total Weight
Odds ratio
M-H, fixed, 95% Cl
0.48 [0.38, 0.61]
No treatment
Figure 2 | Forrest plot comparing pooled incidence of hepatocellular carcinoma (HCC) among lamivudine (LAM)-
treated and untreated patients with chronic hepatitis B virus. The incidence of HCC was signiﬁcantly lower in the
LAM-treated vs. untreated patients (3.3 vs. 9.7 per 100 person years, P < 0.0001).
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cirrhosis (3 vs. 0.3 per 100 person year follow-up) (Fig-
ure 3c). In addition, the pooled HCC rate was 2.5 per
100 person years follow-up among 20 studies (n = 1435)
with CTP-A cirrhosis and 3.6 among 13 studies
(n = 1238) with CTP- B or C cirrhosis (Table S3), but
this difference was not signiﬁcantly different (Figure 3c).
HBeAg status: The HCC incidence was reported sepa-
rately for HBeAg-positive patients in seven studies
(n = 2972) and for HBeAg-negative patients in nine
studies (n = 2215) (Table S3). Although, HBeAg-negative
patients developed HCC more frequently compared with
HBeAg-positive ones (1 vs. 2.3 per 100 person years fol-
low-up), the difference was not signiﬁcant (Figure 3d).
HBV-DNA status: Data based on HBV-DNA status at
the end of the study period or at the time of HCC diag-
nosis were reported separately among 20 studies
(n = 2272) with undetectable HBV-DNA and 21 studies
(n = 2404) with detectable HBV-DNA. The pooled HCC
rate per 100 person years follow-up was nearly twofold
higher (1.9 vs. 1 per 100 person years) among patients
with detectable HBV-DNA compared with patients with
undetectable HBV-DNA (Figure 3e).
Method of HCC detection: Hepatocellular carcinoma
was detected using active cancer surveillance in 28 stud-
ies (n = 3755) and only when prompted by clinical
symptoms in 19 studies (n = 6270) (Table S3). The
0
1
2
3
0
1
2
3
0
2
4
6
0
2
4
6
Age <50 Age >/ = 50
N = 6037 2988
All drugs LAM ADV Others
N = 10 025 5946 1929 2150 
CH      Cirrhosis CTP-A CTP B-C
N = 6129 2848 1535 1313 
HBeAg (+)  HBeAg (–)
N = 2972 2215
0
1
2
3
0
1
2
3
HBVDNA (–) HBVDNA (+)
N = 2272 2404 
HCC screening No screening
N = 3283 6047
Figure 3 | Pooled data on the HCC rate per 100 person years follow-up for: (a) type of drug; (b) age at the start of
treatment; (c) disease severity, (d) hepatitis B E antigen status; (e) HBV-DNA detectability at diagnosis; and (f)
screening method for diagnosis of HCC. The incidence of HCC was not signiﬁcantly different based on the anti-viral
agent used and HBeAg status. However, age was signiﬁcantly associated with HCC incidence [0.9 (0.6–1.2) vs. 2.0
(1.5–2.5)], HBV-DNA detectability at diagnosis [1 (0.6–1.2) vs. 1.9 (1.2–1.6)], method of HCC diagnosis: screening vs.
no screening [1.7 (1.3–2.1) vs. 1.1 (0.6–1.3)] and stage of liver disease: chronic hepatitis vs. cirrhosis [0.3 (0.2–0.4) vs.
3 (2.3–3.6)]. Although the incidence of HCC was higher among the decompensated vs. compensated cirrhotics, this
rate was not signiﬁcantly different [3.6 (2.2–4.9) vs. 2.5 (1.7–3.3)]. Others includes entecavir, telbivudine and
tenofovir. LAM, lamivudine; ADV, adefovir; CH, chronic hepatitis; CTP, Child-Turcotte-Pugh; HCC, hepatocellular
carcinoma.
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incidence of HCC per 100 person years of follow-up was
1.7 when the HCC was detected using the screening
guidelines and 1.1 when HCC was detected on clinical
indication (Figure 3f). Pooled data on most subgroup
analyses were heterogeneous with signiﬁcant publication
bias (Table S3).
Meta-regression
Meta-regression models were built to assess the source of
heterogeneity in the pooled data. Study location (Western
vs. Eastern), age of the patient at enrolment (<50 vs.
>50 years), type of study (randomised vs. nonrando-
mised), study quality and method of HCC detection
(HCC screening or not) were individually assessed as
contributors to study heterogeneity (Table S4). Meta-
regression was performed with stepwise exclusion of the
variable contributing the most heterogeneity with subse-
quent steps being performed on the remaining studies to
recalculate an improved I2 (indicating lower heterogene-
ity). In the ﬁrst step, analysis of pooled data from 49
studies showed that patient age contributed the most to
study heterogeneity (P < 0.0001, Table S4). In the second
step, analysis of 28 studies with mean age of patient at
enrolment >50 years was performed as this had lower I2
compared with 21 studies with age of patient <50 years
(69% vs. 90%; P < 0.0001). A repeat meta-regression
model showed that the study location (Eastern vs. Wes-
tern) contributed the most to the heterogeneity of these
28 pooled studies (P = 0.0063, Table S4). In the third
step, analysis of 15 studies from the Western hemisphere
with age >50 excluded study design variable (P = 0.03)
leaving 12 studies with the most homogeneous data. The
HCC rate on the pooled data from these 12 studies was
1.6 (1.0–2.2) per 100 person years follow-up. As in the
original analysis, the anti-viral agent used did not impact
the HCC rate per 100 person years follow-up: 1.6 (0.7–
2.4) for LAM used in seven studies and 1.7 (0.7–2.6) for
ADV used in the remaining ﬁve studies.
As all the studies did not report HCC incidence data
stratiﬁed by the presence or absence of cirrhosis, HBeAg
status and HBV-DNA status at diagnosis, these variables
were not assessed in the overall meta-regression model.
A separate meta-regression model in the 33 studies of
cirrhotics showed patient age and study quality contrib-
uting the most to pooled heterogeneity. Pooled data from
11 studies with mean patient age of >50 years and poor
study quality were homogeneous with an HCC rate per
100 person years follow-up of 2.4 (1.3–3.4) with no
impact of anti-viral agent used: 2.4 (1.2–3.6) with LAM
used in eight studies, 3.3 (2.5–9.2) with ADV in two
studies and 2.7 (0.4–5.6) with ETV in one study. Similar
analysis on 29 studies on chronic HBV patients without
cirrhosis showed patient age and study design contribut-
ing to the heterogeneity. Pooled data from eight nonran-
domised studies with mean patient age of 50 or more
were homogeneous with an HCC rate per 100 person
years of follow-up of 0.7 (0.5–1.0) without any impact of
type of drug again: 0.7 (0.5–1.0) with LAM in four stud-
ies and 0.8 (0.3–1.8) with ADV in the four remaining
studies. As the number of studies was limited based on
HBeAg status and HBV-DNA detectability, meta-regres-
sion for these subgroups was not performed.
DISCUSSION
The current meta-analysis demonstrates several impor-
tant points regarding the impact of anti-viral therapy on
the incidence of HCC in chronic HBV patients. Firstly,
LAM treatment for a median of 43 months reduces the
incidence of HCC by more than 50% from 9.7% per year
in untreated controls to 3.3% per year in LAM-treated
chronic hepatitis B (CHB) patients. Our pooled data in
6877 (3306 treated) patients demonstrate a similar mag-
nitude of beneﬁt to that achieved in the pivotal RCT of
LAM.5 These ﬁndings further support recommendations
regarding the need for indeﬁnite therapy in chronic
HBV patients with advanced histology to improve
patient outcomes.2
Secondly, the overall incidence of HCC was 1.4% in
the data pooled from over 10 000 patients treated with
an oral anti-viral agent, but did not differ by the agent
prescribed. Our inability to discern a difference among
the various agents is similar to reports from individual
centres.16 Lastly, our data demonstrate that HCC occurs
more frequently among chronic HBV patients receiving
oral anti-viral therapy who are older, have cirrhosis and
in those with persistently detectable HBV-DNA at the
end of treatment or at the time of HCC diagnosis. These
data conﬁrm the importance of continuous suppression
of HBV replication to improve patient outcomes. Lastly,
contrary to prior studies of untreated chronic HBV
patients, our data show that the incidence of HCC did
not signiﬁcantly differ by HBeAg status, and the pres-
ence of decompensation among the cirrhotic patients.
Prior retrospective studies by Fattovich et al. have
shown the incidence of HCC among untreated Western
chronic HBV patients to be proportional to the severity
of underlying liver disease with rates of 0.04, 0.3, and 2.2
per 100 person years follow-up among asymptomatic
carriers, CHB and compensated cirrhotics respectively.17
Similar HCC rates have been reported among untreated
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Asian patients with HCC rate of 0.5, 0.6 and 3.7 per 100
person years follow-up respectively.18 In the current
meta-analysis, the pooled HCC rate was lowest among
chronic HBV patients without cirrhosis at only 0.3% per
100 person years, and 3% per 100 person years among
cirrhotics, but did not differ in those with decompensat-
ed vs. compensated disease (3.6 vs. 2.5 per 100 person
years). The low observed rate among the noncirrhotic
patients is rather remarkable considering that all of these
patients had chronic active hepatitis with active viral rep-
lication mandating the initiation of anti-viral treatment.
We surmise that the noncirrhotic patients included in
this analysis inevitably had more severe liver disease than
the untreated chronic carriers reported in the literature.
Nonetheless, these data demonstrate that even in the
presence of anti-viral therapy, HCC may still develop
albeit at a lower rate.
Cirrhosis is a known risk factor for development of
HCC and is considered to be a premalignant condi-
tion.2, 19 However, nearly 10–20% of chronic HBV
patients with HCC do not have cirrhosis at the time of
diagnosis.20 In the current analysis, the incidence of
HCC was nearly 10-fold higher in cirrhotics compared
with patients without cirrhosis. Similar data have been
reported from prospective natural history studies where
the incidence of HCC was four to ﬁvefold higher among
untreated HBV cirrhotics compared with asymptomatic
carriers.21 Therefore, continued HCC surveillance is war-
ranted in chronic HBV patients with advanced ﬁbrosis
who are started on anti-viral therapy.
In the current analysis, the pooled HCC rate was sig-
niﬁcantly higher among studies that used prospective
surveillance for HCC compared with studies that relied
upon clinical symptoms to prompt investigation. These
data reiterate the recommendations of various profes-
sional societies regarding the importance of periodic sur-
veillance to detect and diagnose HCC in an early and
potentially treatable stage. Other risk factors for HCC
development in the current analysis were increased age
at enrolment and the inability to suppress HBV-DNA to
undetectable levels. Patient age is known to be risk factor
for many malignancies including HCC associated with
chronic HBV and HCV.22 This is likely due to a longer
duration of infection with consequent prolonged patho-
genic effect of the virus on the liver. Higher HBV-DNA
level is also known to be a factor for the HCC develop-
ment in untreated chronic HBV patients of Asian ethnic-
ity.3 Studies have shown an HCC rate of <1% with
baseline HBV-DNA of 300–10 000 copies/mL and 13.5%
with baseline HBV-DNA of >106 copies/mL during a
mean follow-up of 11.4 years.23 Although, we could not
analyse the effect of baseline HBV-DNA due to inconsis-
tent reporting of the data and use of varying assays, our
data demonstrated a lower incidence of HCC among
patients with undetectable HBV-DNA during treatment
compared with patients with detectable HBV-DNA at
the end of study or at the time of HCC detection
(including patients with virological breakthrough). These
data are similar to prospective studies showing lower
HCC rate among patients with undetectable HBV-DNA
treated with interferon.2, 24, 25
Hepatitis B e antigen status in this study did not sig-
niﬁcantly inﬂuence the incidence of HCC. Data from
previous studies on the impact of HBeAg on the inci-
dence of HCC have been conﬂicting. In the Eurohep
study, HBeAg (+) status did not impact the incidence of
HCC. However, other studies have reported higher HCC
rate among HBeAg-positive patients.26 The lack of corre-
lation of HBeAg status with the HCC rate in this analy-
sis could be due to the small number of studies
reporting HCC incidence based on HBeAg status (seven
for HBeAg positive and nine for HBeAg negative). In
addition, it is possible that suppression of HBV replica-
tion may reduce the importance of this marker. Severity
of disease and stage of cirrhosis also did not affect the
HCC rate in our analysis. We speculated that decompen-
sated patients may be dying from complications of cir-
rhosis such as ascites or variceal bleeding before the
development of HCC. However, a prior meta-analysis on
the safety and efﬁcacy of the oral anti-viral agents in
patients with decompensated cirrhosis showed a global
improvement in patient survival in those treated with
LAM vs. untreated controls.6
Limitations of this study include our inability to obtain
patient level data to look at the individual predictive fac-
tors in a multivariate manner. In addition, there was sub-
stantial heterogeneity among the studies when pooled
together. Our meta-regression suggests that the heteroge-
neity was, in part, due to age of the patient at enrolment,
study design and study location (Eastern or Western
hemisphere). Furthermore, it should be noted that the
sensitivity of the HBV-DNA assays used in the pooled
studies varied substantially between studies. Therefore,
our conﬁdence in the observation of persistently detect-
able HBV-DNA as a predictor of HCC development
should be interpreted with caution. Lastly, the absence of
an observed difference in the incidence of HCC stratiﬁed
by the speciﬁc drug used may, in part, be due to pooling
data for patients treated with ETV, TBV and TDF due to
limited number of patients treated with respective drug.
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As the newer oral anti-viral agents such as ETV and TDF
are more potent and associated with a lower rate of drug
resistance, we had anticipated to see a difference. How-
ever, the absence of a difference could also be confounded
by differences in the proportion of patients with other
environmental factors (alcohol use and smoking), viral
factors (HBV genotype and baseline HBV-DNA level)
and patient factors (age, disease severity). Of note, the
studies with newer anti-viral agents included signiﬁcantly
younger patients, which may have reduced the observed
rate of HCC. Finally, the limited duration of follow-up in
the studies included in this analysis may have prevented
us from detecting a difference with the newer anti-viral
agents, which may prove more effective with less drug
resistance after 5–10 years of continuous treatment.
In summary, our meta-analysis demonstrates that
LAM therapy is associated with a 56% reduction in the
incidence of HCC among chronic HBV patients com-
pared with no treatment. In addition, among patients
receiving an oral anti-viral agent, subject age, the pres-
ence of cirrhosis and method of HCC detection all sig-
niﬁcantly impact the incidence of HCC. Finally,
although we did not observe a difference in the inci-
dence of HCC based on the individual agent prescribed,
additional prospective studies are needed that control
for the confounders of subject age, gender, cirrhosis
and HCC detection method to better estimate the risk
of developing HCC among those receiving the newer
anti-viral agents.
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